Advaxis to conduct 4 cancer immunotherapy clinical trials with GRU Cancer Center Advaxis announced it has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center to conduct four Phase 1/2 clinical trials. The planned trials will further develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer. The planned trials will further develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer. The four clinical trials will be designed to assess: High dose, repeating cycles of ADXS-HPV in recurrent or refractory cervical cancer. ADXS-cHER2 in women with Her2/neu over-expressing breast cancer with measurable disease who have progressed after prior standard therapy. The optimal combination dose of ADXS-HPV and PD-1 antibody in patients with recurrent or refractory cervical cancer. ADXS-HPV prior to surgery in patients with surgically treatable cervical cancer.
Advaxis to receive $1.6M through NJ NOL Program Advaxis announced the company has received preliminary approval for a $1.8M tax credit from the New Jersey Technology Business Tax Certificate Transfer, or NOL, Program for the year 2015. The company anticipates it will be able to transfer this credit and receive approximately $1.6M in cash in December.